Skip to content

Partial rescue of F508del-cystic fibrosis transmembrane conductance regulator channel gating with modest improvement of protein processing, but not stability, by a dual-acting small molecule

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1017-1038
Number of pages22
JournalBritish Journal of Pharmacology
Volume175
Issue number7
Early online date22 Feb 2018
DOIs
DateAccepted/In press - 10 Dec 2017
DateE-pub ahead of print - 22 Feb 2018
DatePublished (current) - Apr 2018

Abstract

Background and purpose. Rescue of F508del-cystic fibrosis transmembrane conductance regulator (CFTR), the most common cystic fibrosis (CF) mutation, requires small molecules that overcome protein processing, stability and channel gating defects. Here, we investigate F508del-CFTR rescue by CFFT-004 (from WO2010/068863), a small molecule designed to independently correct protein processing and channel gating defects.

Experimental approach. Using CFTR-expressing recombinant cells and CF patient-derived bronchial epithelial cells, we studied CFTR expression by Western blotting and channel gating and stability with the patch-clamp and Ussing chamber techniques.

Key results. Chronic treatment with CFFT-004 improved modestly F508del-CFTR processing, but not its plasma membrane stability. By contrast, CFFT-004 rescued F508del-CFTR channel gating better than C18, an analogue of the clinically-used CFTR corrector lumacaftor. Subsequent acute addition of CFFT-004, but not C18, potentiated F508del-CFTR channel gating. However, CFFT-004 was without effect on A561E-CFTR, a CF mutation with a comparable mechanism of CFTR dysfunction as F508del-CFTR. To investigate the mechanism of action of CFFT-004, we used F508del-CFTR revertant mutations. Potentiation by CFFT-004 was unaffected by revertant mutations, but correction was abolished by the revertant mutation G550E. These data suggest that correction, but not potentiation by CFFT-004 might involve nucleotide-binding domain 1 of CFTR.

Conclusions and implications. CFFT-004 is a dual-acting small molecule with independent corrector and potentiator activities that partially rescues F508del-CFTR in recombinant cells and native airway epithelia. The limited efficacy and potency of CFFT-004 suggests that combinations of small molecules targeting different defects in F508del-CFTR might be a more effective therapeutic strategy than a single agent.

    Research areas

  • ATP-binding cassette transporter, CFTR, chloride ion channel, cystic fibrosis, F508del-CFTR, CFTR processing, channel gating, stability, revertant mutations, CFTR corrector-potentiator (dual-acting small molecule)

Download statistics

No data available

Documents

Documents

  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Wiley at https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.14141 . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 8 MB, PDF-document

    Licence: Unspecified

DOI

View research connections

Related faculties, schools or groups